Lipid lowering effects of Momordica charantia (Bitter Melon) in HIV-1-protease inhibitor-treated human hepatoma cells, HepG2

British Journal of Pharmacology

Volumn 148, Issue 8, 2006, Pages 1156-1164

  Nerurkar, Pratibha V ^a   Lee, Yun Kyung ^a,b   Linden, Ellen H ^a   Lim, Steven ^a   Pearson, Laurel ^a,b   Frank, Jennifer ^c   Nerurkar, Vivek R ^b  

^a UNIVERSITY OF HAWAII AT MANOA   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c UNIVERSITY OF HAWAII   (United States)

Author keywords

apoA I; apoB; apoC III; Apolipoproteins; Bitter melon; HAART; Hyperlipidemia; Lopinavir; Ritonavir; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; LOPINAVIR PLUS RITONAVIR; MESSENGER RNA; MOMORDICA CHARANTIA EXTRACT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DIET THERAPY; DRUG EFFICACY; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERLIPIDEMIA; IN VITRO STUDY; MOMORDICA CHARANTIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; PROTEIN SECRETION; QUALITY OF LIFE;

ANTILIPEMIC AGENTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS E; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA PRIMERS; HIV PROTEASE INHIBITORS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; LIVER NEOPLASMS; MOMORDICA CHARANTIA; RNA, MESSENGER;

EID: 33747105897     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706821     Document Type: Article

References (69)

1. AHMED, I., LAKHANI, M.S., GILLETT, M., JOHN, A. & RAZA, H. (2001). Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract., 51, 155-161.
2. AHMED, N., HASSAN, M.R., HALDER, H. & BENNOOR, K.S. (1999). Effect of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med. Res. Counc. Bull., 25, 11-13.
3. ANILA, L. & VIJAYALAKSHMI, N.R. (2000). Beneficial effects of flavonoids from Sesamum indicum, Emblica officinalis and Momordica charantia. Phytother. Res., 14, 592-595.
4. BADIOU, S., DE BOEVER, C.M., DUPUY, A.M., BAILLAT, V., CRISTOL, J.P. & REYNES, J. (2003a). Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir/ritonavir-containing regimen. AIDS, 17, 772-774.
5. BADIOU, S., MERLE DE BOEVER, C., DUPUY, A.M., BAILLAT, V., CRISTOL, J.P. & REYNES, J. (2003b). Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis, 168, 107-113.
6. BASCH, E., GABARDI, S. & ULBRICHT, C. (2003). Bitter melon (Momordica charantia): a review of efficacy and safety. Am. J. Health. Syst. Pharm., 60, 356-359.
7. BONNET, E., RUIDAVETS, J.B., TUECH, J., FERRIERES, J., COLLET, X., FAUVEL, J., MASSIP, P. & PERRET, B. (2001). Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy. J. Clin. Endocrinol. Metab., 86, 296-302.
8. BORRADAILE, N.M., DE DREU, L.E., BARRETT, P.H. & HUFF, M.W. (2002). Inhibition of hepatocyte apoB secretion by naringenin: enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J. Lipid. Res., 43, 1544-1554.
9. CARPENTIER, A., PATTERSON, B.W., UFFELMAN, K.D., SALIT, I. & LEWIS, G.F. (2005). Mechanism of highly active anti-retroviral therapy-induced hyperlipidemia in HIV-infected individuals. Atherosclerosis, 178, 165-172.
10. CARR, A. (2003). Cardiovascular risk factors in HIV-infected patients. J. Acq. Immun. Def. Synd., 34 (Suppl 1), S73-8.
11. CARR, A., SAMARAS, K., THORISDOTTIR, A., KAUFMANN, G.R., CHISHOLM, D.J. & COOPER, D.A. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet, 353, 2093-2099.
12. CASASCHI, A., MAIYOH, G.K., RUBIO, B.K., LI, R.W., ADELI, K. & THERIAULT, A.G. (2004a). The chalcone xanthohumol inhibits triglyceride and apolipoprotein B secretion in HepG2 cells. J. Nutr., 134, 1340-1346.
13. CASASCHI, A., RUBIO, B.K., MAIYOH, G.K. & THERIAULT, A.G. (2004b). Inhibitory activity of diacylglycerol acyltransferase (DGAT) and microsomal triglyceride transfer protein (MTP) by the flavonoid, taxifolin, in HepG2 cells: potential role in the regulation of apolipoprotein B secretion. Atherosclerosis, 176, 247-253.
14. CHAN, L.L., CHEN, Q., GO, A.G., LAM, E.K. & LI, E.T. (2005). Reduced adiposity in bitter melon (Momordica charantia)-fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J. Nutr., 135, 2517-2523.
15. CHAO, C.Y. & HUANG, C.J. (2003). Bitter gourd (Momordica charantia) extract activates peroxisome proliferator-activated receptors and upregulates the expression of the acyl CoA oxidase gene in H4IIEC3 hepatoma cells. J. Biomed. Sci., 10, 782-791.
16. CHEN, Q. & LI, E.T. (2005). Reduced adiposity in bitter melon (Momordica charantia) fed rats is associated with lower tissue triglyceride and higher plasma catecholamines. Br. J. Nutr., 93, 747-754.
17. CHEN, Q., CHAN, L.L. & LI, E.T. (2003). Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr., 133, 1088-1093.
18. DIXON, J.L., FURUKAWA, S. & GINSBERG, H.N. (1991). Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem., 266, 5080-5086.
19. DUBE, M.P., SPRECHER, D., HENRY, W.K., ABERG, J.A., TORRIANI, F.J., HODIS, H.N., SCHOUTEN, J., LEVIN, J., MYERS, G., ZACKIN, R., NEVIN, T. & CURRIER, J.S. (2000). Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis., 31, 1216-1224.
20. EL-SADR, W.M., MULLIN, C.M., CARR, A., GIBERT, C., RAPPOPORT, C., VISNEGARWALA, F., GRUNFELD, C. & RAGHAVAN, S.S. (2005). Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med., 6, 114-121.
21. FAUVEL, J., BONNET, E., RUIDAVETS, J.B., FERRIERES, J., TOFFOLETTI, A., MASSIP, P., CHAP, H. & PERRET, B. (2001). An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. Aids, 15, 2397-2406.
22. FICHTENBAUM, C.J. & GERBER, J.G. (2002). Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet., 41, 1195-1211.
23. HAAS, M.J., HORANI, M.H., WONG, N.C. & MOORADIAN, A.D. (2004). Induction of the apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. Metabolism, 53, 1342-1348.
24. HADIGAN, C. (2003). Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy. Clin. Infect. Dis., 37 (Suppl 2), S101-S104.
25. HADIGAN, C., JESTE, S., ANDERSON, E.J., TSAY, R., CYR, H. & GRINSPOON, S. (2001). Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin. Infect. Dis., 33, 710-717.
26. HAUBENWALLNER, S., ESSENBURG, A.D., BARNETT, B.C., PAPE, M.E., DEMATTOS, R.B., KRAUSE, B.R., MINTON, L.L., AUERBACH, B.J., NEWTON, R.S. & LEFF, T. et al. (1995). Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action. J. Lipid. Res., 36, 2541-2551.
27. HIGASHI, Y., ITABE, H., FUKASE, H., MORI, M., FUJIMOTO, Y., SATO, R., IMANAKA, T. & TAKANO, T. (2002). Distribution of microsomal triglyceride transfer protein within sub-endoplasmic reticulum regions in human hepatoma cells. Biochim. Biophys. Acta, 1581, 127-136.
28. HUSSAIN, M.M., MAXFIELD, F.R., MAS-OLIVA, J., TABAS, I., JI, Z.S., INNERARITY, T.L. & MAHLEY, R.W. (1991). Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. J. Biol. Chem., 266, 13936-13940.
29. JAYASOORIYA, A.P., SAKONO, M., YUKIZAKI, C., KAWANO, M., YAMAMOTO, K. & FUKUDA, N. (2000). Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharmacol., 72, 331-336.
30. JONG, M.C., RENSEN, P.C., DAHLMANS, V.E., VAN DER BOOM, H., VAN BERKEL, T.J. & HAVEKES, L.M. (2001). Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J. Lipid. Res., 42, 1578-1585.
31. KAPLAN, S.S. & HICKS, C.B. (2005). Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection. Expert. Opin. Pharmacother., 6, 1573-1585.
32. KHANNA, P., JAIN, S.C., PANAGARIYA, A. & DIXIT, V.P. (1981). Hypoglycemic activity of polypeptide-p from a plant source. J. Nat. Prod., 44, 648-655.
33. KOEBNICK, C., GARCIA, A.L., DAGNELIE, P.C., STRASSNER, C., LINDEMANS, J., KATZ, N., LEITZMANN, C. & HOFFMANN, I. (2005). Long-term consumption of a raw food diet is associated with favorable serum LDL cholesterol and triglycerides but also with ELEVATED plasma homocysteine and low serum HDL cholesterol in humans, 2. J. Nutr., 135, 2372-2378.
34. LEATHERDALE, B.A., PANESAN, R.K., SINGH, G., ATKINS, T.W., BAILEY, C.J. & BIGNELL, A.H. (1981). Improvement in glucose tolerance due to Momordica charantia (karela). Br. Med. J. (Clin. Res. Ed.), 282, 1823-1824.
35. LENHARD, J.M., CROOM, D.K., WEIEL, J.E. & WINEGAR, D.A. (2000). HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler. Thromb. Vasc. Biol., 20, 2625-2629.
36. LEOW, M.K., ADDY, C.L. & MANTZOROS, C.S. (2003). Clinical review 159: human immunodeficiency virus/highly active antiretroviral therapy-associated metabolic syndrome: clinical presentation, pathophysiology, and therapeutic strategies. J. Clin. Endocrinol. Metab., 88, 1961-1976.
37. LIANG, J.S., DISTLER, O., COOPER, D.A., JAMIL, H., DECKELBAUM, R.J., GINSBERG, H.N. & STURLEY, S.L. (2001). HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat. Med., 7, 1327-1331.
38. MALAVAZI, I., ABRAO, E.P., MIKAWA, A.Y., LANDGRAF, V.O. & DA COSTA, P.I. (2004). Abnormalities in apolipoprotein and lipid levels in an HIV-infected Brazilian population under different treatment profiles: the relevance of apolipoprotein E genotypes and immunological status. Clin. Chem. Lab. Med., 42, 525-532.
39. MARLES, R.J. & FARNSWORTH, N.R. (1995). Antidiabetic plants and their active constituents. Phytomedicine, 2, 137-189.
40. MCCARTY, M.F. (2004). Does bitter melon contain an activator of AMP-activated kinase? Med. Hypotheses, 63, 340-343.
41. MEHTA, N. & REILLY, M. (2005). Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin. Trials, 6, 5-24.
42. MONTES, M.L., PULIDO, F., BARROS, C., CONDES, E., RUBIO, R., CEPEDA, C., DRONDA, F., ANTELA, A., SANZ, J., NAVAS, E., MIRALLES, P., BERENGUER, J., PEREZ, S., ZAPATA, A., GONZALEZ-GARCIA, J.J., PENA, J.M., VAZQUEZ, J.J. & ARRIBAS, J.R. (2005). Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J. Antimicrob. Chemother., 55, 800-804.
43. MOOSER, V. & CARR, A. (2001). Antiretroviral therapy-associated hyperlipidaemia in HIV disease. Curr. Opin. Lipidol., 12, 313-319.
44. MULLIGAN, K., GRUNFELD, C., TAI, V.W., ALGREN, H., PANG, M., CHERNOFF, D.N., LO, J.C. & SCHAMBELAN, M. (2000). Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acq. Immun. Def. Synd., 23, 35-43.
45. NARAYAN, S., HAWLEY, N., GIGUERE, P. & BADLEY, A.D. (2003). Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors. HIV Clin. Trials, 4, 164-169.
46. NERAD, J., ROMEYN, M., SILVERMAN, E., ALLEN-REID, J., DIETERICH, D., MERCHANT, J.A., PELLETIER, V., TINNERELLO, D. & FENTON, M. (2003). General nutrition management in patients infected with human immunodeficiency virus. Clin. Infect. Dis., 36 (Suppl 2), S52-S62.
47. NERURKAR, P.V., DRAGULL, K. & TANG, C.S. (2004). In vitro toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. Toxicol. Sci., 79, 106-111.
48. NERURKAR, P.V., PEARSON, L., EFIRD, J.T., ADELI, K., THERIAULT, A.G. & NERURKAR, V.R. (2005). Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells. J. Nutr., 135, 702-706.
49. PALELLA JR, F.J., DELANEY, K.M., MOORMAN, A.C., LOVELESS, M.O., FUHRER, J., SATTEN, G.A., ASCHMAN, D.J. & HOLMBERG, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N. Engl. J. Med., 338, 853-860.
50. RAJ, S.K., KHAN, M.S., SINGH, R., KUMARI, N. & PRAKASH, D. (2005). Occurrence of yellow mosaic geminiviral disease on bitter gourd (Momordica charantia) and its impact on phytochemical contents. Int. J. Food Sci. Nutr., 56, 185-192.
51. RAZA, H., AHMED, I., LAKHANI, M.S., SHARMA, A.K., PALLOT, D. & MONTAGUE, W. (1996). Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats. Biochem. Pharmacol., 52, 1639-1642.
52. RIDDLE, T.M., SCHILDMEYER, N.M., PHAN, C., FICHTENBAUM, C.J. & HUI, D.Y. (2002). The HIV protease inhibitor ritonavir increases lipoprotein production and has no effect on lipoprotein clearance in mice. J. Lipid Res., 43, 1458-1463.
53. RIMLAND, D., GUEST, J.L., HERNANDEZ, I., DEL RIO, C., LE, N.A. & BROWN, W.V. (2005). Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins. HIV Med., 6, 326-333.
54. ROCHE, R., POIZOT-MARTIN, I., YAZIDI, C.M., COMPE, E., GASTAUT, J.A., TORRESANI, J. & PLANELLS, R. (2002). Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS, 16, 13-20.
55. SAVES, M., RAFFI, F., CAPEAU, J., ROZENBAUM, W., RAGNAUD, J.M., PERRONNE, C., BASDEVANT, A., LEPORT, C. & CHENE, G. (2002). Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin. Infect. Dis., 34, 1396-1405.
56. SAX, P.E. & GATHE JR, J.C. (2005). Beyond efficacy: the impact of combination antiretroviral therapy on quality of life. AIDS Patient Care STDS, 19, 563-576.
57. SCHARNAGL, H., SCHINKER, R., GIERENS, H., NAUCK, M., WIELAND, H. & MARZ, W. (2001). Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem. Pharmacol., 62, 1545-1555.
58. SEKHAR, R.V., JAHOOR, F., POWNALL, H.J., REHMAN, K., GAUBATZ, J., IYER, D. & BALASUBRAMANYAM, A. (2005). Severely dysregulated disposal of postprandial triacylglycerols exacerbates hypertriacylglycerolemia in HIV lipodystrophy syndrome. Am. J. Clin. Nutr., 81, 1405-1410.
59. SENANAYAKE, G.V., MARUYAMA, M., SHIBUYA, K., SAKONO, M., FUKUDA, N., MORISHITA, T., YUKIZAKI, C., KAWANO, M. & OHTA, H. (2004). The effects of bitter melon (Momordica charantia) on serum and liver triglyceride levels in rats. J. Ethnopharmacol., 91, 257-262.
60. SHACHTER, N.S. (2001). Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Curr. Opin. Lipidol., 12, 297-304.
61. SRIVASTAVA, Y., VENKATAKRISHNA-BHATT, H., VERMA, Y., VENKAIAH, K. & RAVAL, B.H. (1993). Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother. Res., 7, 285-289.
62. STEIN, J.H., MERWOOD, M.A., BELLEHUMEUR, J.B., MCBRIDE, P.E., WIEBE, D.A. & SOSMAN, J.M. (2005). Postprandial lipoprotein changes in patients taking antiretroviral therapy for HIV infection. Arterioscler. Thromb. Vasc. Biol., 25, 399-405.
63. UMESH, C.S., MOORTHY, Y.K. & BAQUER, N.Z. (2005). Combined treatment of sodium orthovanadate and Momordica charantia fruit extract prevents alterations in lipid profile and lipogenic enzymes in alloxan diabetic rats. Mol. Cell. Biochem., 268, 111-120.
64. VIRDI, J., SIVAKAMI, S., SHAHANI, S., SUTHAR, A.C., BANAVALIKAR, M.M. & BIYANI, M.K. (2003). Antihyperglycemic effects of three extracts from Momordica charantia. J. Ethnopharmacol., 88, 107-111.
65. WANG, Y., TRAN, K. & YAO, Z. (1999). The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins. J. Biol. Chem., 274, 27793-27800.
66. WELIHINDA, J., KARUNANAYAKE, E.H., SHERIFF, M.H. & JAYASINGHE, K.S. (1986). Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J. Ethnopharmacol., 17, 277-282.
67. YOUNG, B. (2005). Review: mixing new cocktails: drug interactions in antiretroviral regimens. AIDS Patient Care STDS, 19, 286-297.
68. YU, L.X., AMIDON, G.L., POLLI, J.E., ZHAO, H., MEHTA, M.U., CONNER, D.P., SHAH, V.P., LESKO, L.J., CHEN, M.L. & LEE, V.H. (2002). Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. (New York), 19, 921-925.
69. ZANG, M., ZUCCOLLO, A., HOU, X., NAGATA, D., WALSH, K., HERSCOVITZ, H., BRECHER, P., RUDERMAN, N.B. & COHEN, R.A. (2004). AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem., 279, 47898-47905.